Nu Skin Swings to Profit on Mavely Sale, Despite Revenue Dip

TL;DR

**Nu Skin's profit surge is a one-time sugar rush from an asset sale; don't get fooled by the headline, core business is still shrinking.**

AI Summary

NU SKIN ENTERPRISES, INC. (NUS) reported a significant turnaround in net income for the nine months ended September 30, 2025, reaching $145.7 million, a substantial improvement from a net loss of $110.5 million in the same period of 2024. This positive shift was largely driven by a $176.2 million gain on the sale of its Mavely entity to Clout.io Holdings, Inc. on January 2, 2025, which generated net proceeds of $193.7 million. Despite this, revenue for the nine-month period decreased by 13.3% to $1.11 billion from $1.29 billion in 2024. For the three months ended September 30, 2025, net income more than doubled to $17.1 million from $8.3 million in 2024, even as quarterly revenue declined by 15.3% to $364.2 million from $430.1 million. The company also reduced its long-term debt by $154.6 million, from $363.6 million at December 31, 2024, to $209.0 million at September 30, 2025, and saw an increase in cash and cash equivalents to $251.8 million from $186.9 million. Operating income for the nine months ended September 30, 2025, was $42.5 million, a significant recovery from an operating loss of $98.5 million in the prior year.

Why It Matters

This filing reveals Nu Skin's strategic pivot, divesting its Mavely entity for a substantial gain, which significantly bolstered its bottom line and cash position. While the one-time gain is positive, the persistent decline in core revenue, down 13.3% year-over-year, indicates ongoing challenges in its direct selling beauty and wellness segments. Investors should scrutinize whether the company can reignite organic growth to sustain profitability post-Mavely. Competitors in the beauty and wellness space, particularly those with stronger digital direct-to-consumer models, may continue to pressure Nu Skin's market share if its core business doesn't stabilize.

Risk Assessment

Risk Level: medium — The company's revenue declined by 13.3% for the nine months ended September 30, 2025, to $1.11 billion from $1.29 billion in 2024, indicating ongoing operational challenges. While the $176.2 million gain on the sale of Mavely boosted net income, this is a non-recurring event, and the underlying business performance shows weakness.

Analyst Insight

Investors should view the recent profit surge with caution, recognizing it's largely due to the Mavely sale. Focus on future quarterly revenue trends and management's strategy to reverse the 13.3% year-over-year revenue decline in the core business. Consider holding or reducing exposure until there's clear evidence of sustainable organic growth.

Financial Highlights

debt To Equity

0.26

revenue

$1.11 billion

operating Margin

3.8%

total Assets

$1.42 billion

total Debt

$229.0 million

net Income

$145.7 million

eps

$3.05

gross Margin

69.0%

cash Position

$251.8 million

revenue Growth

-13.3%

Revenue Breakdown

Key Numbers

• $145.7M — Net income for nine months ended Sept 30, 2025 (Significant turnaround from a $110.5M net loss in 2024)
• $176.2M — Gain on sale of business (Resulted from the sale of Mavely on January 2, 2025)
• $1.11B — Revenue for nine months ended Sept 30, 2025 (Decreased by 13.3% from $1.29B in 2024)
• $364.2M — Revenue for three months ended Sept 30, 2025 (Decreased by 15.3% from $430.1M in 2024)
• $251.8M — Cash and cash equivalents as of Sept 30, 2025 (Increased from $186.9M at Dec 31, 2024)
• $209.0M — Long-term debt as of Sept 30, 2025 (Reduced from $363.6M at Dec 31, 2024)
• $42.5M — Operating income for nine months ended Sept 30, 2025 (Recovery from a $98.5M operating loss in 2024)
• 48,750,076 — Shares of Class A common stock outstanding (As of November 1, 2025)

Key Players & Entities

• NU SKIN ENTERPRISES, INC. (company) — registrant
• Clout.io Holdings, Inc. (company) — purchaser of Mavely
• Mavely (company) — entity sold by Nu Skin
• FASB (regulator) — issues accounting standards
• New York Stock Exchange (regulator) — exchange where NUS is listed
• SEC (regulator) — securities regulator

FAQ

Risk Factors

• Geopolitical and Economic Instability [high — market]: The company operates globally and is exposed to risks from geopolitical tensions, trade disputes, and economic downturns in key markets like China and Southeast Asia. These factors can disrupt supply chains, reduce consumer spending, and negatively impact revenue and profitability.
• Evolving Regulatory Landscape [medium — regulatory]: Changes in regulations related to direct selling, product safety, and advertising in various countries can increase compliance costs and restrict market access. For instance, stricter rules in China have previously impacted operations.
• Supply Chain Disruptions [medium — operational]: The company relies on a global supply chain for its products. Disruptions due to natural disasters, pandemics, or geopolitical events can lead to inventory shortages and increased costs, impacting the ability to meet customer demand.
• Foreign Currency Fluctuations [medium — financial]: Operating in multiple countries exposes NUS to foreign currency exchange rate fluctuations. Adverse movements can negatively affect reported revenues and profits when translated back to U.S. dollars.
• Intense Competition [high — market]: The beauty and wellness industry is highly competitive, with numerous players offering similar products. NUS faces competition from both established brands and emerging direct-to-consumer companies, requiring continuous innovation and marketing efforts.
• Dependence on Key Markets [high — operational]: A significant portion of the company's revenue is derived from a few key geographic markets, particularly Mainland China. Any adverse changes in these markets, such as economic slowdowns or regulatory shifts, can disproportionately impact overall financial performance.
• E-commerce and Digital Transformation [medium — operational]: The shift towards e-commerce and digital sales channels requires continuous investment in technology and adaptation of sales strategies. Failure to keep pace with digital trends could lead to a loss of market share.
• Inventory Management [medium — financial]: Managing inventory levels effectively is crucial. Overstocking can lead to obsolescence and write-downs, while understocking can result in lost sales. The company's inventory was $178.5 million as of September 30, 2025, down from $190.2 million at the end of 2024.

Industry Context

Nu Skin operates in the highly competitive global beauty and wellness direct selling industry. Key trends include a growing consumer demand for personalized products, increasing importance of digital channels and social commerce, and a heightened focus on sustainability and ethical sourcing. The industry is characterized by significant marketing spend and a reliance on independent distributors to reach consumers.

Regulatory Implications

The direct selling model is subject to scrutiny and evolving regulations in various jurisdictions, particularly concerning marketing claims and distributor compensation. Nu Skin must navigate these complex regulatory environments, which can impact its business practices and market access, especially in key regions like China.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]
4. [object Object]
5. [object Object]

Key Dates

• 2025-01-02: Sale of Mavely entity — Generated a significant gain of $176.2 million, substantially improving net income for the nine-month period. This divestiture signals a strategic shift or focus on core operations.
• 2025-09-30: End of Q3 2025 — Reporting period for the 10-Q. Key financial metrics like revenue, net income, cash, and debt levels are presented as of this date.
• 2025-11-01: Shares outstanding reported — Provides the number of Class A common shares outstanding (48,750,076), crucial for per-share calculations and understanding market capitalization.
• 2024-12-31: End of Fiscal Year 2024 — Baseline for comparison of financial health, showing $186.9 million in cash and $363.6 million in long-term debt.
• 2024-09-30: End of Q3 2024 — Prior year period for comparison, showing a net loss of $110.5 million and an operating loss of $98.5 million, highlighting the significant turnaround.

Glossary

Operating income (loss)

Profitability from a company's core business operations before accounting for interest and taxes. It reflects the efficiency of day-to-day business activities. (Shows a significant recovery from a loss of $98.5 million in the prior year's nine-month period to a gain of $42.5 million in 2025, indicating improved operational performance.)

Gain on sale of business

The profit realized from selling a business or a significant part of it. This is typically a non-recurring item. (A $176.2 million gain from the sale of Mavely was the primary driver of the net income turnaround in the nine months ended September 30, 2025.)

Current assets

Assets that are expected to be converted into cash, sold, or consumed within one year or the operating cycle, whichever is longer. (Total current assets were $548.1 million as of September 30, 2025, a slight increase from $538.6 million at the end of 2024, indicating stable short-term liquidity.)

Current liabilities

Obligations that are due within one year or the operating cycle. (Total current liabilities decreased to $254.4 million from $296.6 million at the end of 2024, improving the company's short-term financial position.)

Treasury stock

Stock that a company has repurchased from the open market. It is recorded at cost and appears as a contra-equity account. (The company held $1.57 billion in treasury stock as of September 30, 2025, reflecting past share repurchase programs.)

Retained earnings

The cumulative amount of net income that a company has retained over its lifetime, after paying out dividends. (Retained earnings increased to $1.85 billion as of September 30, 2025, from $1.71 billion at the end of 2024, driven by the net income generated in the period.)

Goodwill

An intangible asset that arises when one company acquires another for a price greater than the fair market value of its identifiable net assets. (Goodwill remained stable at $83.6 million, indicating no significant acquisitions or impairments during the period.)

Other intangible assets, net

Intangible assets such as patents, trademarks, and copyrights, net of accumulated amortization. (These decreased from $74.3 million at the end of 2024 to $44.2 million as of September 30, 2025, likely due to amortization or write-downs.)

Year-Over-Year Comparison

Compared to the nine months ended September 30, 2024, Nu Skin Enterprises, Inc. has shown a dramatic turnaround in profitability, shifting from a net loss of $110.5 million to a net income of $145.7 million, largely due to a $176.2 million gain on the sale of its Mavely entity. However, revenue has declined by 13.3% to $1.11 billion, indicating ongoing challenges in core sales. Operating income has recovered significantly from a loss of $98.5 million to a gain of $42.5 million. The company has also strengthened its balance sheet by reducing long-term debt by $154.6 million and increasing its cash position by $64.9 million.

Filing Documents

• ef20054961_10q.htm (10-Q) — 2073KB
• ef20054961_ex31-1.htm (EX-31.1) — 10KB
• ef20054961_ex31-2.htm (EX-31.2) — 10KB
• ef20054961_ex32-1.htm (EX-32.1) — 4KB
• ef20054961_ex32-2.htm (EX-32.2) — 4KB
• 0001140361-25-040839.txt ( ) — 9330KB
• nus-20250930.xsd (EX-101.SCH) — 41KB
• nus-20250930_cal.xml (EX-101.CAL) — 79KB
• nus-20250930_def.xml (EX-101.DEF) — 255KB
• nus-20250930_lab.xml (EX-101.LAB) — 700KB
• nus-20250930_pre.xml (EX-101.PRE) — 426KB
• ef20054961_10q_htm.xml (XML) — 1868KB

Financial Statements (Unaudited)

Financial Statements (Unaudited): Consolidated Balance Sheets 1 Consolidated Statements of Income 2 Consolidated Statements of Comprehensive Income 3 Consolidated Statements of Stockholders' Equity 4 Consolidated Statements of Cash Flows 6

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 20 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 30 Item 4.

Controls and Procedures

Controls and Procedures 30 Part II. Other Information Item 1.

Legal Proceedings

Legal Proceedings 31 Item 1A.

Risk Factors

Risk Factors 31 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 31 Item 3. Defaults Upon Senior Securities 32 Item 4. Mine Safety Disclosures 32 Item 5. Other Information 32 Item 6. Exhibits 32 Signature 33 In this Quarterly Report on Form 10-Q, references to "dollars" and "$" are to United States ("U.S.") dollars. Nu Skin, Pharmanex, and ageLOC are our trademarks. The italicized product names used in this Quarterly Report on Form 10-Q are product names and also, in certain cases, our trademarks. Table of Contents PART I. FINANCIAL INFORMATION ITEM 1.

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS NU SKIN ENTERPRISES, INC. Consolidated Balance Sheets (Unaudited) (U.S. dollars in thousands) September 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 251,787 $ 186,883 Current investments 1,210 11,111 Accounts receivable, net 48,892 50,784 Inventories, net 178,533 190,242 Prepaid expenses and other 67,721 72,643 Current assets held for sale — 26,936 Total current assets 548,143 538,599 Property and equipment, net 375,280 379,595 Operating lease right-of-use assets 79,933 72,605 Goodwill 83,625 83,625 Other intangible assets, net 44,198 74,278 Other assets 293,227 298,008 Long-term assets held for sale — 22,204 Total assets $ 1,424,406 $ 1,468,914 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 28,523 $ 34,880 Accrued expenses 205,914 217,808 Current portion of long-term debt 20,000 30,000 Current liabilities held for sale — 13,919 Total current liabilities 254,437 296,607 Operating lease liabilities 62,382 58,439 Long-term debt 209,044 363,613 Other liabilities 98,748 97,475 Long-term liabilities held for sale — 1,325 Total liabilities 624,611 817,459 Commitments and contingencies (Notes 6 and 12) Stockholders' equity: Class A common stock – 500 million shares authorized, $ 0.001 par value, 90.6 million shares issued 91 91 Additional paid-in capital 633,161 627,787 Treasury stock, at cost – 41.5 million and 40.8 million shares ( 1,565,275 ) ( 1,563,614 ) Accumulated other comprehensive loss ( 116,916 ) ( 124,758 ) Retained earnings 1,848,734 1,711,949 Total stockholders' equity 799,795 651,455 Total liabilities and stockholders' equ ity $ 1,424,406 $ 1,468,914 The accompanying notes are an integral part of these consolidated financial statements. 1 Table of Contents NU SKIN ENTERPRISES, INC. Consolid

Financial Statements

Financial Statements 1. The Company Nu Skin Enterprises, Inc. (the "Company") is a holding company, with Nu Skin being the primary operating unit. Nu Skin develops and distributes premium-quality, innovative beauty and wellness products that are sold worldwide primarily under the Nu Skin, Pharmanex and ageLOC brands. The Company reports revenue from nine segments, consisting of its seven geographic Nu Skin segments —Americas, which includes Canada, Latin America and the United States; Mainland China; Southeast Asia/Pacific, which includes Indonesia, Malaysia, the Philippines, Singapore, Thailand , Vietnam , Australia, New Zealand, and other markets; Japan; Europe and Africa, which includes markets in Europe as well as South Africa; South Korea; and Hong Kong/Taiwan, which also includes Macau—and two Rhyz segments—Manufacturing, which includes manufacturing and packaging subsidiaries it has acquired; and Rhyz Other, which includes other investments by its Rhyz business arm (the Company's subsidiaries operating within each segment are collectively referred to as the "Subsidiaries"). 2. Summary of Significant Accounting Policies The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP") for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by US GAAP for complete financial statements. The unaudited consolidated financial statements include the accounts of the Company and its Subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. In the opinion of management, the accompanying unaudited consolidated financial statements contain all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company's financial information as of S